Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination

• 出版年: Research and Practice in Thrombosis and Haemostasis
• 主要な著者: Rezvan Hosseinzadeh, Mohammad Barary, Hamed Mehdinezhad, Terence T. Sio, Florian Langer, Sahar Khosravi
• フォーマット: 論文
• 言語: 英語
• 出版事項: Elsevier 2022-05-01
• 主題: COVID‐19; SARS‐CoV‐2; Sinopharm; thrombosis; vaccine; VITT
• オンライン･アクセス: https://doi.org/10.1002/rth2.12750

Abstract Background Severe side effects after vaccination with coronavirus disease 2019 (COVID‐19) vaccines are rare but can be fatal. To date, vaccine‐induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID‐19 vaccines. Here, we report the second suspected case of VITT after vaccination with the Sinopharm vaccine, an inactive vaccine. Key Clinical Question The Key Clinical Question was to determine whether inactivated COVID‐19 vaccines could induce VITT and how to diagnose and treat such cases. Clinical Approach and Conclusions Our patient developed deteriorating symptoms the day after vaccination and was admitted to the emergency department on day 5 after vaccination. After performing laboratory analysis, thrombosis with thrombocytopenia was suggested, further confirmed by highly positive anti‐heparin–platelet factor 4 antibodies assay and color Doppler ultrasonography. He was then treated with high‐dose intravenous immunoglobulin, corticosteroid, and nonheparin anticoagulant.